The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis
Open accessAbstract
Background and aims: The incidence of irritable bowel syndrome (IBS) or functional bowel disorders (FBD) after bacillary dysentery (BD) has not been extensively evaluated, and little is known of the pathogenesis of post-infective (PI) IBS. Therefore, we investigated the incidence of IBS and FBD in a Chinese patient population who had recovered from BD. To further elucidate its pathogenesis, neuroimmunological changes, including interleukins (IL), mast cells, neuropeptides, and the relationship between mast cells and intestinal nerves, were investigated. Methods: A cohort study of 295 patients who had recovered from BD (shigella identified from stool in 71.4%) and 243 control subjects consisting of patient siblings or spouses who had not been infected with BD were included in the study. All subjects were followed up using questionnaires for 1–2 years to explore the incidence of FBD and IBS, as defined by the Rome II criteria. In 56 cases of IBS (PI and non-PI) from another source, the number of mast cells in biopsy specimens from the intestinal mucosa were stained with antitryptase antibody and counted under light microscopy. Also, the relationship of mast cells to neurone specific enolase (NSE), substance P (SP), 5-hydroxytryptamine (5-HT), or calcitonin gene related peptide positive nerve fibres was observed using double staining with alcian blue and neuropeptide antibodies. In 30 cases of IBS (PI-IBS, n = 15) taken at random from the 56 cases, expression of interleukin (IL)-1α, IL-1β, and IL-1 receptor antagonist (IL-1ra) mRNAs in intestinal mucosa were identified using reverse transcription-polymerase chain reaction. The above results were compared with 12 non-IBS controls. Results: In the BD infected cohort, the incidences of FBD and IBS were 22.4% and 8.1% (in total)–10.2% (among those in who shigella were identified) respectively, which were significantly higher (p<0.01) than the incidences of FBD (7.4%) and IBS (0.8%) in the control cohort. A longer duration of diarrhoea (⩾7 days) was associated with a higher risk of developing FBD (odds ratio 3.49 (95% confidence interval 1.71–7.13)). Expression of IL-1β mRNA in terminal ileum and rectosigmoid mucosa was significantly higher in PI-IBS patients (p<0.01). The number of mast cells in the terminal ileum mucosa in PI-IBS (11.19 (2.83)) and non-PI-IBS patients (10.78 (1.23)) was significantly increased compared with that (6.05 (0.51)) in control subjects (p<0.01). Also, in the terminal ileum and rectosigmoid mucosa of IBS patients, the density of NSE, SP, and 5-HT positively stained nerve fibres increased (p<0.05) and appeared in clusters, surrounding an increased number of mast cells (p<0.01 compared with controls). Conclusions: BD is a causative factor in PI-IBS. The immune and nervous system may both play important roles in the pathogenesis of PI-IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have demonstrated increased concentrations of activated mast cells in patients with IBS compared with controls (11, 13, 24, 46, 89, 94, 121, 187).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [187]
In the citing paper
“Notably, some studies demonstrated an increase in activated mast cells in biopsies from specific regions of the GI tract (i.e., cecum and terminal ileum) but not from other regions (e.g., ascending colon, descending colon, rectum) (89, 121, 187), whereas other studies have found activated mast cells in the descending colon (11, 13).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [187]
In the citing paper
“Levels of interleukin (IL)-1β mRNA may be increased in the small intestine, colon, and rectum of patients with PI-IBS compared with healthy controls (75, 187), supporting the hypothesis that low-grade inflammation is present in patients with PI-IBS.”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [187]
In the citing paper
“The importance of the interaction between the intestinal microbiota and immune system in IBS patients is demonstrated by a few studies in patients with PI-IBS, indicating activation of the GI immune system following the acute GI infection (57, 58, 75, 89, 94, 124, 168, 170, 187)”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Gut flora in health and disease
Guarner, F., & Malagelada, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,480
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Use of Unlinked Genetic Markers to Detect Population Stratification in Association Studies
Pritchard, J. K., & Rosenberg, N. A. (1999) · The American Journal of Human Genetics · doi:10.1086/302449 · Cited by 1,198
Population stratification and spurious allelic association
Cardon, L. R., & Palmer, L. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12520-2 · Cited by 1,189
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155
Hampe, J., Cuthbert, A. P., Croucher, P. J. P., Mirza, M. M., Mascheretti, S., Fisher, S. A., Frenzel, H., King, K., Hasselmeyer, A., Macpherson, A. J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05063-7 · Cited by 1,090
Grölund, M., Lehtonen, O. ‐., Eerola, E., & Kero, P. O. (1999) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199901000-00007 · Cited by 873
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833
Flagged first, then by citations
Research works printed but not linked: 8
- 2000, Chinese Med J, 113, 35
- Drossman D A. The functional GI disorders and the Rome II process. In: Drossman DA, et al, eds. The functional gastrointestinal disorders, 2nd edn. USA: Allen Press, 2000:1–30. · DOI
- 1999, Gut, 45, II43
- 1994, Gastroenterology, 106, A523
- 1998, Nature, 334, 698
- 10.1053/gast.2002.37071 · DOI
- 2000, News Physiol Sci, 15, 213
- 2002, Am J Physiol, 283, G612
Cited by
Sorted by citations
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M. D., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 1,102
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Intestinal barrier function in health and gastrointestinal disease
Camilleri, M., Madsen, K., Spiller, R., Van Meerveld, B. G., & Verne, G. N. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01921.x · Cited by 908
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions
Öhman, L., & Simrén, M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.4 · Cited by 617
Klem, F., Wadhwa, A., Prokop, L. J., Sundt, W. J., Farrugia, G., Camilleri, M., Singh, S., & Grover, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.039 · Cited by 474
THABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Mearin, F., Pérez-Oliveras, M., Juan, A. P., Vinyet, J., Ibañez, A., Coderch, J., & Perona, M. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.012 · Cited by 406
Marshall, J. K., Thabane, M., Garg, A. X., Clark, W., Salvadori, M., & Collins, S. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.053 · Cited by 304
“These records included the following: (1) individual responses to a survey of 899 Walkerton residents conducted by the local Bruce-Gray-Owen Sound Health Unit once the outbreak was recognized, (2) regional hospital laboratory data, (3) pharmacy records, (4) family physician charts, and ( 5 ) Walkerton Hospital medical…”
Fundamentals of Neurogastroenterology: Basic Science
Vanner, S. J., Meerveld, B. G., Mawe, G. M., Shea‐Donohue, T., Verdu, E. F., Wood, J. D., & Grundy, D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.018 · Cited by 364
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351
Mechanisms of hypersensitivity in IBS and functional disorders
Azpiroz, F., Bouin, M., Camilleri, M., Mayer, E. A., Poitras, P., Serra, J., & Spiller, R. E. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00875.x · Cited by 367
Postinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352
“This is consistent with the current literature, which suggests that IGE associated with invasive bacterial etiologies and severity of initial infection are important predictors of developing IBS (16, 21).”
ResultGecse, K., Róka, R., Ferrier, L., Leveque, M., Eutamene, H., Cartier, C., Ait-Belgnaoui, A., Rosztóczy, A., Izbéki, F., Fioramonti, J., et al. (2008) · Gut · doi:10.1136/gut.2007.140210 · Cited by 314
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308
Crouzet, L., Gaultier, E., Del'Homme, C., Cartier, C., Delmas, E., Dapoigny, M., Fioramonti, J., & Bernalier‐Donadille, A. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12103 · Cited by 280
Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome
Barbara, G., Grover, M., Berčík, P., Corsetti, M., Ghoshal, U. C., Öhman, L., & Rajilić-Stojanović, M. D. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.011 · Cited by 298
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome
Zhou, Q., Souba, W. W., Croce, C. M., & Verne, G. N. (2009) · Gut · doi:10.1136/gut.2009.181834 · Cited by 285
Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report
Riddle, M. S., Connor, B. A., Beeching, N. J., DuPont, H. L., Hamer, D. H., Kozarsky, P. E., Libman, M., Steffen, R. J., Taylor, D. N., Tribble, D. R., et al. (2017) · Journal of Travel Medicine · doi:10.1093/jtm/tax026 · Cited by 275
Irritable bowel syndrome: A clinical review
Soares, R. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12144 · Cited by 266
Fundamentals of Neurogastroenterology: Basic Science
Grundy, D., Al–Chaer, E. D., Aziz, Q., Collins, S. M., Ke, M., Taché, Y., & Wood, J. D. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.060 · Cited by 242
van der Veek, P. P. J., van den Berg, M., de Kroon, Y. E., Verspaget, H. W., & Masclee, A. A. M. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00257.x · Cited by 217
Matricon, J., Méleine, M., Gelot, A., Piche, T., Dapoigny, M. C., Muller, E., & Ardid, D. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12080 · Cited by 216
Cremonini, F., & Talley, N. J. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.02.008 · Cited by 215
Irritable bowel syndrome: Diagnosis and pathogenesis
El‐Salhy, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i37.5151 · Cited by 222
The immune system in irritable bowel syndrome
Barbara, G., Cremon, C., Carini, G., Bellacosa, L., Zecchi, L., Giorgio, R. D., Corinaldesi, R., & Stanghellini, V. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.4.349 · Cited by 211
“cells, including tryptase and histamine, have an increased potential to affect neural function.(47,56) The biological significance of mast cells and mediators re-”
Is Irritable Bowel Syndrome a Low-Grade Inflammatory Bowel Disease?
Berčík, P., Verdu, E. F., & Collins, S. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.02.007 · Cited by 207
“A recent study confirmed increased IL-1b levels, structural changes in enteric nerves, and increased mast cell counts in biopsies from patients with postinfectious IBS [32].”
BackgroundWheatcroft, J., Wakelin, D., Smith, A., Mahoney, C. R., Mawe, G., & Spiller, R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00719.x · Cited by 205
Piche, T., Saint-Paul, M. C., Dainese, R., Marine-Barjoan, E., Iannelli, A., Montoya, M. L., Peyron, J. F., Czerucka, D., Cherikh, F., Filippi, J., et al. (2008) · Gut · doi:10.1136/gut.2007.127068 · Cited by 198
Ford, A., & Talley, N. (2011) · Journal of gastroenterology · doi:10.1007/s00535-011-0379-9 · Cited by 187
Clinical significance of lymph node metastasis in gastric cancer
Deng, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3967 · Cited by 198
Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes
Hughes, P. A., Harrington, A. M., Castro, J., Liebregts, T., Adam, B., Grasby, D. J., Isaacs, N. J., Maldeniya, L., Martin, C. M., Persson, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301856 · Cited by 195
Irritable bowel syndrome in developing countries – a disorder of civilization or colonization?
Gwee, K. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00627.x · Cited by 193
Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019) · Gut · doi:10.1136/gutjnl-2017-315136 · Cited by 195
Post-infectious irritable bowel syndrome
Thabane, M. E., & Marshall, J. K. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3591 · Cited by 211
Marshall, J. K., Thabane, M., Garg, A. X., Clark, W. F., Moayyedi, P., Collins, S. M., & Walkerton Health Study Investigators (2010) · Gut · doi:10.1136/gut.2009.202234 · Cited by 227
Review article: probiotics and prebiotics in irritable bowel syndrome
SPILLER, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03750.x · Cited by 190
Role of infection in irritable bowel syndrome
Spiller, R. C. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-006-1925-8 · Cited by 187
Irritable bowel syndrome: Emerging paradigm in pathophysiology
Lee, Y. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2456 · Cited by 190
Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study
Wensaas, K., Langeland, N., Hanevik, K., Mørch, K., Eide, G. E., & Rørtveit, G. (2011) · Gut · doi:10.1136/gutjnl-2011-300220 · Cited by 184
Crosstalk at the mucosal border: importance of the gut microenvironment in IBS
Öhman, L., Törnblom, H., & Simrén, M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.200 · Cited by 185
Functional gastrointestinal disorders and mast cells: implications for therapy
Barbara, G., Stanghellini, V., Giorgio, R. D., & Corinaldesi, R. (2006) · Neurogastroenterology and Motility · doi:10.1111/j.1365-2982.2005.00685.x · Cited by 194
Spiller, R. E., & Lam, C. (2012) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2012.18.3.258 · Cited by 179
Asian consensus on irritable bowel syndrome
Gwee, K., Bak, Y., Ghoshal, U. C., Gonlachanvit, S., Lee, O. Y., Fock, K. M., Chua, A. S. B., Lu, C., Goh, K., Kositchaiwat, C., et al. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06353.x · Cited by 172
Lee, K. J., Kim, Y. B., Kim, J. H., Kwon, H. C., Kim, D. K., & Cho, S. W. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05574.x · Cited by 171
Epidemiology of irritable bowel syndrome in Asia: Something old, something new, something borrowed
Gwee, K., Lu, C., & Ghoshal, U. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05984.x · Cited by 171
Immune dysfunction in patients with functional gastrointestinal disorders
Kindt, S., Van Oudenhove, L., Broekaert, D., Kasran, A., Ceuppens, J. L., Bossuyt, X., Fischler, B., & Tack, J. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01220.x · Cited by 165
Symptomatic overlap between irritable bowel syndrome and microscopic colitis
Limsui, D., Pardi, D. S., Camilleri, M., Loftus, E. V., Kammer, P. P., Tremaine, W. J., & Sandborn, W. J. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20059 · Cited by 167
T-Cell Activation in Patients With Irritable Bowel Syndrome
Öhman, L., Isaksson, S., Lindmark, A.-C., Posserud, I., Stotzer, P.-O., Strid, H., Sjövall, H., & Simrén, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.116 · Cited by 165
“Furthermore, individuals who develop IBS after an infectious gastroenteritis have increased expression of the proinflammatory cytokine IL-1β mRNA in rectal biopsies (”
BackgroundDothel, G., Barbaro, M. R., Boudin, H., Vasina, V. I., Cremon, C., Gargano, L., Bellacosa, L., GIORGIO, R. D., Berre‐Scoul, C. L., Aubert, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.042 · Cited by 167
“SH-SY5Y cells treated with Hank’s buffer were used as calibrator and relative gene expression was calculated as ∆∆Ct.(23) The levels of GAP43 gene expression were expressed as fold difference (2).”
MethodColonic immune cells in irritable bowel syndrome: A systematic review and meta‐analysis
Bashashati, M., Moossavi, S., Cremon, C., Barbaro, M. R., Moraveji, S., Talmon, G., Rezaei, N., Hughes, P. A., Bian, Z. X., Choi, C. H., et al. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13192 · Cited by 175
Hanevik, K., Wensaas, K., Rørtveit, G., Eide, G. E., Mørch, K., & Langeland, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu629 · Cited by 158
“the eliciting gastroenteritis has been shown to be a risk factor for development of PI-IBS [39] and has also been found in this cohort [40].”
Barreau, F., Ferrier, L., Fioramonti, J., & Bueno, L. P. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e3180db2949 · Cited by 156
“Indeed, in the ileum and rectosigmoid mucosa of IBS patients, the density of neuron specific enolase, substance P, and serotonin positively stained nerve fibers was increased and appeared in clusters, surrounding an increased number of mast cells (74).”
BackgroundResultNew insights into the pathogenesis and pathophysiology of irritable bowel syndrome
Öhman, L., & Simrén, M. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.10.014 · Cited by 155
“The incidence of post-infectious IBS after enteric infecion has been reported to vary between 3% to approximately 5% [144,148–155].”
BackgroundImmune Activation in Irritable Bowel Syndrome: Can Neuroimmune Interactions Explain Symptoms?
Hughes, P. A., Zola, H., Penttila, I., Blackshaw, L. A., Andrews, J. M., & Krumbiegel, D. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.120 · Cited by 147
Intestinal permeability and irritable bowel syndrome
Camilleri, M., & Gorman, H. (2007) · Neurogastroenterology and Motility · doi:10.1111/j.1365-2982.2007.00925.x · Cited by 145
Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome
Barbara, G., Cremon, C., GIORGIO, R. D., Dothel, G., Zecchi, L., Bellacosa, L., Carini, G., Stanghellini, V., & Corinaldesi, R. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0195-7 · Cited by 153
“In the latter, nerve fibers appeared in clusters surrounding an increased number of mast cells [77].”
BackgroundO’Malley, D., Quigley, E. M. M., Dinan, T. G., & Cryan, J. F. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.04.009 · Cited by 140
“, 2000) and mast cells (Wang et al., 2004) and the degree of immune activation is linked to the severity of the infective gastroen-”
BackgroundGrover, M., Herfarth, H., & Drossman, D. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.032 · Cited by 131
A Global Perspective on Irritable Bowel Syndrome
Quigley, E. M. M., Abdel-Hamid, H., Barbara, G., Bhatia, S. J., Boeckxstaens, G. E., GIORGIO, R. D., Delvaux, M. M., Drossman, D. A., Foxx–Orenstein, A. E., Guarner, F., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318247157c · Cited by 131
Barreau, F., Salvador‐Cartier, C., Houdeau, E., Bueno, L., & Fioramonti, J. (2008) · Gut · doi:10.1136/gut.2007.126680 · Cited by 133
“Moreover, afferent nerves exert a trophic effect on intestinal mast cells.”
BackgroundJung, H., Choung, R. S., Locke, R. G., Schleck, C. D., Zinsmeister, A. R., & Talley, N. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.621 · Cited by 128
Intestinal immune activation in presumed post‐infectious functional dyspepsia
Kindt, S., Tertychnyy, A. S., Hertogh, G. D., Geboes, K. J., & Tack, J. F. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01299.x · Cited by 126
Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome
Aerssens, J., Camilleri, M., Talloen, W., Thielemans, L., Göhlmann, H. W. H., Van den Wyngaert, I., Thielemans, T., De Hoogt, R., Andrews, C. N., Bharucha, A. E., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.11.012 · Cited by 124
Infection, inflammation, and the irritable bowel syndrome
Spiller, R., & Garsed, K. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.07.007 · Cited by 122
Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients
Schoepfer, A. M., Schaffer, T., Seibold‐schmid, B., Müller, S., & Seibold, F. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01166.x · Cited by 120
Stermer, E., Lubezky, A., Potasman, I., Paster, E., & Lavy, A. (2006) · Clinical Infectious Diseases · doi:10.1086/507540 · Cited by 120
“One study went further and established infection with Shigella species as the cause of postinfectious IBS in 8% of cases [6].”
BackgroundApplied Principles of Neurogastroenterology: Physiology/Motility Sensation
Kellow, J. E., Azpiroz, F., Delvaux, M. M., Gebhart, G. F., Mertz, H. R., Quigley, E. M. M., & Smout, A. J. P. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.08.061 · Cited by 117
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome
Ringel, Y., & Maharshak, N. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00207.2012 · Cited by 115
“The importance of the interaction between the intestinal microbiota and immune system in IBS patients is demonstrated by a few studies in patients with PI-IBS, indicating activation of the GI immune system following the acute GI infection (57, 58, 75, 89, 94, 124, 168, 170, 187), and the recent animal studies showing…”
BackgroundResultInfluentialNeuroanatomy of lower gastrointestinal pain disorders.
Vermeulen, W., Man, J. G. D., Pelckmans, P., & de Winter, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.1005 · Cited by 105
New Insights into the Pathogenesis and Pathophysiology of Irritable Bowel Syndrome
Collins, S. M. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3314-6_9 · Cited by 115
Second Asian Consensus on Irritable Bowel Syndrome
Gwee, K., Gonlachanvit, S., Ghoshal, U. C., Chua, A. S. B., Miwa, H., Wu, J. C. Y., Bak, Y., Lee, O. Y., Lu, C., Park, H., et al. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19041 · Cited by 112
“8% among controls.(75) In a study from Seoul investigating an outbreak of Shigella infection among 181 health-care”
BackgroundSelf-citationNeuropathophysiology of functional gastrointestinal disorders
Wood, J. D. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i9.1313 · Cited by 111
Recent developments in the pathophysiology of irritable bowel syndrome
El-Salhy, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7621 · Cited by 111
Systematic review: the influence of geography and ethnicity in irritable bowel syndrome
Kang, J. Y. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02396.x · Cited by 110
Schwille-Kiuntke, J., Enck, P., Zendler, C., Krieg, M., Polster, A. V., Klosterhalfen, S., Autenrieth, I. B., Zipfel, S., & Frick, J.-S. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01779.x · Cited by 110
Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome
Qin, H., Wu, J. C. Y., Tong, X.-D., Sung, J. J. �., Xu, H., & Bian, Z. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0321-6 · Cited by 111
Beatty, J. K., Bhargava, A., & Buret, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3976 · Cited by 292
Diet in irritable bowel syndrome
El‐Salhy, M., & Gundersen, D. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0022-3 · Cited by 115
“Several types of endocrine cell in all segments of the gastrointestinal tract of IBS patients are abnormal [108-129].”
BackgroundMast cell mediation of visceral sensation and permeability in irritable bowel syndrome
Hasler, W. L., Grabauskas, G., Singh, P., & Owyang, C. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14339 · Cited by 105
Thabane, M., Simunovic, M., Akhtar-Danesh, N., Garg, A. X., Clark, W. F., Collins, S. M., Salvadori, M., & Marshall, J. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.74 · Cited by 120
Inflammation in irritable bowel syndrome: Myth or new treatment target?
Sinagra, E., Pompei, G., Tomasello, G., Cappello, F., Morreale, G. C., Amvrosiadis, G., Rossi, F., Monte, A. I. L., Rizzo, A. G., & Raimondo, D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2242 · Cited by 104
Wadhwa, A., Alnahhas, M. F., Dierkhising, R., Patel, R., Kashyap, P., Pardi, D. S., Khanna, S., & Grover, M. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13737 · Cited by 102
Carco, C., Young, W., Gearry, R. B., Talley, N. J., McNabb, W. C., & Roy, N. C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00468 · Cited by 105
“Salmonella (McKendrick and Read, 1994), Shigella (Gwee et al., 1999; Wang et al., 2004) or Escherichia coli (Marshall et al.”
BackgroundIrritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management
Gwee, K., Ghoshal, U., & Chen, M.-H. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13987 · Cited by 103
Postinfectious Irritable Bowel Syndrome
Ericsson, C. D., Hatz, C., & DuPont, A. W. (2008) · Clinical Infectious Diseases · doi:10.1086/526774 · Cited by 103
“Increased IL-1b expression in the rectosigmoid and ileum has been found in patients with postinfectious IBS following Shigella infection, and normal levels have been seen in patients with IBS without an infectious onset [5].”
BackgroundIs irritable bowel syndrome an organic disorder?
El‐Salhy, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.384 · Cited by 95
Immune dysregulation in the functional gastrointestinal disorders
Keely, S., Walker, M. M., Marks, E., & Talley, N. J. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12548 · Cited by 96
Rostami, A., Riahi, S. M., Haghighi, A. N., Saber, V., Armon, B., & Tabaei, S. J. S. (2017) · Parasitology Research · doi:10.1007/s00436-017-5535-6 · Cited by 102
“…Tehran, Iran 5 Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran system perception of pain are proposed as potential mechanisms of IBS (Cann et al. 1983; Kassinen et al. 2007; Stanghellini et al. 2002; Tillisch et al. 2011; Wang et al. 2004).”
BackgroundPost-infectious irritable bowel syndrome
Spiller, R., & Campbell, E. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000194792.36466.5c · Cited by 39
The Role of Eosinophils and Mast Cells in Intestinal Functional Disease
Walker, M. M., Warwick, A., Ung, C. Y., & Talley, N. J. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0197-5 · Cited by 90
“However, both showed a marked increase in mast cells over controls [ 44 ].”
BackgroundTachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human
Lecci, A., Capriati, A., Altamura, M., & Maggi, C. A. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.02.014 · Cited by 91
Update on human Campylobacter jejuni infections
Kirkpatrick, B. D., & Tribble, D. R. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283413763 · Cited by 91
Review article: probiotics in gastrointestinal and liver diseases
Jonkers, D. M. A. E., & Stockbrügger, R. W. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03480.x · Cited by 89
Bugs and irritable bowel syndrome: The good, the bad and the ugly
Ghoshal, U. C., Park, H., & Gwee, K. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06133.x · Cited by 88
Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships
Yuan, Y., Wang, X., Huang, S., Wang, H., & Shen, G.-M. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2263209 · Cited by 104
“Increased numbers of MC were found in the terminal ileum and rectosigmoid mucosa of IBS patients.(15) mucosal biopsies from IBS patients released mediators, of which MC secretory products 5-HT, histamine and trypsin-like levels were higher than in controls.”
BackgroundTalley, N. J. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01217.x · Cited by 87
Post‐Infectious Sequelae of Travelers' Diarrhea
Connor, B. A., & Riddle, M. S. (2013) · Journal of Travel Medicine · doi:10.1111/jtm.12049 · Cited by 88
The Role of Mast Cells in Irritable Bowel Syndrome
Lee, K. N., & Lee, O. Y. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2031480 · Cited by 90
“Moreover, these enteric nerves were found to contain the mediators, 5hydroxytryptamine (5-HT), calcitonin gene-related peptide (CGRP), and substance P (SP) [59].”
Background
Metadata
- Authors
- Wang, L.-H., Fang, X.-C., & Pan, G.-Z.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Pan, G-Z
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-07-09
- Volume
- 53
- Issue
- 8
- Pages
- 1096-1101
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC1774156
- OpenAlex
- W2158018898
- Cited by
- 387
- References
- 51
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 9 · 2020: 10 · 2019: 17 · 2018: 17 · 2017: 18 · 2016: 19 · 2015: 19 · 2014: 31 · 2013: 18 · 2012: 23
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Gut (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- shigellosis, irritable bowel syndrome, functional bowel disorders, Shigella, mast cells, neuroimmunology, substance P, calcitonin gene-related peptide, serotonin, interleukin-1, interleukin-1 receptor antagonist, intestinal nerves, pathogenesis, diarrhea duration
- MeSH terms
- Adult, Colonic Diseases, Functional, Diarrhea, Dysentery, Bacillary, Female, Follow-Up Studies, Humans, Interleukin-1, Intestinal Mucosa, Male, Mast Cells, Nerve Fibers, Phosphopyruvate Hydratase, Risk Factors, Serotonin, Substance P, Calcitonin Gene-Related Peptide, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
